Spots Global Cancer Trial Database for recentin
Every month we try and update this database with for recentin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX | NCT00384176 | Colorectal Canc... | Cediranib Bevacizumab 5-fluorouracil ... Leucovorin (in ... Oxaliplatin (in... | 18 Years - 130 Years | AstraZeneca | |
| Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours | NCT00264004 | Tumors | AZD2171 | 18 Years - | AstraZeneca | |
| Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer | NCT00399035 | Metastatic Colo... | Cediranib FOLFOX (5-fluor... XELOX (Capecita... Cediranib Place... | 18 Years - 130 Years | AstraZeneca | |
| Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients | NCT00621361 | Lung Cancer | AZD2171 Etoposide Cisplatin | 18 Years - | AstraZeneca | |
| Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX) | NCT00278889 | Colorectal Canc... | AZD2171 5-fluorouracil Leucovorin Oxaliplatin Bevacizumab | 18 Years - | AstraZeneca | |
| A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX | NCT00494221 | Metastatic Colo... | AZD2171 FOLFOX (5-fluor... Placebo Cediran... | 18 Years - | AstraZeneca | |
| Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer | NCT00399035 | Metastatic Colo... | Cediranib FOLFOX (5-fluor... XELOX (Capecita... Cediranib Place... | 18 Years - 130 Years | AstraZeneca | |
| The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer | NCT00243347 | Carcinoma Non-Small-Cell ... Head and Neck N... | AZD2171 | 18 Years - | AstraZeneca | |
| Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX) | NCT00278889 | Colorectal Canc... | AZD2171 5-fluorouracil Leucovorin Oxaliplatin Bevacizumab | 18 Years - | AstraZeneca | |
| DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study) | NCT00748891 | Cancer | Recentin (Cedir... | 18 Years - | AstraZeneca | |
| Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™) | NCT00306891 | Cancer | Cediranib Cediranib 30 - ... | 18 Years - | AstraZeneca | |
| Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients | NCT00621361 | Lung Cancer | AZD2171 Etoposide Cisplatin | 18 Years - | AstraZeneca | |
| The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). | NCT00385203 | Gastrointestina... Soft Tissue Sar... | AZD2171 | 18 Years - | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
